BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23812723)

  • 1. Values of MMP-2 and MMP-9 in tumor tissue of basal-like breast cancer patients.
    Radenkovic S; Konjevic G; Jurisic V; Karadzic K; Nikitovic M; Gopcevic K
    Cell Biochem Biophys; 2014 Jan; 68(1):143-52. PubMed ID: 23812723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of MMP-2 and MMP-9 in sera of breast cancer patients.
    Stankovic S; Konjevic G; Gopcevic K; Jovic V; Inic M; Jurisic V
    Pathol Res Pract; 2010 Apr; 206(4):241-7. PubMed ID: 20092959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
    Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
    Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
    Sliwowska I; Kopczyński Z
    Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
    Ueno H; Nakamura H; Inoue M; Imai K; Noguchi M; Sato H; Seiki M; Okada Y
    Cancer Res; 1997 May; 57(10):2055-60. PubMed ID: 9158005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation.
    Wang F; Reierstad S; Fishman DA
    Cancer Lett; 2006 May; 236(2):292-301. PubMed ID: 16019136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
    Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
    Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera.
    La Rocca G; Pucci-Minafra I; Marrazzo A; Taormina P; Minafra S
    Br J Cancer; 2004 Apr; 90(7):1414-21. PubMed ID: 15054465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
    Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
    Hum Pathol; 2006 Oct; 37(10):1316-23. PubMed ID: 16949931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
    Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA
    Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients.
    Puzovic V; Brcic I; Ranogajec I; Jakic-Razumovic J
    Neoplasma; 2014; 61(4):439-46. PubMed ID: 24645837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer.
    Liu SC; Yang SF; Yeh KT; Yeh CM; Chiou HL; Lee CY; Chou MC; Hsieh YS
    Clin Chim Acta; 2006 Sep; 371(1-2):92-6. PubMed ID: 16581051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer.
    Dalberg K; Eriksson E; Enberg U; Kjellman M; Bäckdahl M
    World J Surg; 2000 Mar; 24(3):334-40. PubMed ID: 10658069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer.
    Kawamura K; Kamiya N; Suyama T; Shimbo M; Oosumi N; Suzuki H; Ueda T; Tobe T; Igarashi T; Ito H; Ishikura H
    J Urol; 2004 Oct; 172(4 Pt 1):1480-4. PubMed ID: 15371875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active MMP-2 effectively identifies the presence of colorectal cancer.
    Murnane MJ; Cai J; Shuja S; McAneny D; Klepeis V; Willett JB
    Int J Cancer; 2009 Dec; 125(12):2893-902. PubMed ID: 19551856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional electrophoresis.
    Pucci-Minafra I; Minafra S; La Rocca G; Barranca M; Fontana S; Alaimo G; Okada Y
    Matrix Biol; 2001 Nov; 20(7):419-27. PubMed ID: 11691582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors.
    Hanemaaijer R; Verheijen JH; Maguire TM; Visser H; Toet K; McDermott E; O'Higgins N; Duffy MJ
    Int J Cancer; 2000 Apr; 86(2):204-7. PubMed ID: 10738247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring gelatinase activity in colorectal cancer.
    Baker EA; Leaper DJ
    Eur J Surg Oncol; 2002 Feb; 28(1):24-9. PubMed ID: 11869009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
    Daniele A; Zito AF; Giannelli G; Divella R; Asselti M; Mazzocca A; Paradiso A; Quaranta M
    Anticancer Res; 2010 Sep; 30(9):3521-7. PubMed ID: 20944132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.